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A CASE OF ADRENAL CORTICAL CARCINOMA 
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Koushou T AKASU 
From the Detartment 01 Pathology，めotoCity Ho判tal
We report a case of left adrenocortical carcinoma in a 23-year-old man. His chief complaints 
were spike fever attack and general malaise. Imaging examination revealed a heterogeneously 
enhanced mass at the site of the left adrenal gland. Non-functional adrenocortical carcinoma was 
suspected from hormonal studies. The mass was removed together with the left kidney because of 
severe adhesion to the renal pedicle. The histopathological findings showed adrenocortical carcinoma 
(pT3NOMO). Three months after surgery， local recurrence appeared and the tumor grew larger 
rapidly. Spike fever attack reappeared. No distant metastasis was detected. Two courses of 
systemic chemotherapy with 0， p'ーDDD，VP-16， adriamycin and cisplatinum were performed. 
Computed tomography after the chemotherapy showed progression. Although 0， p'-DDD was 
administered continuously， the patient died of cancerous cachexia 8 months after the surgery. 
Autopsy could not be done. 
(Acta Urol. Jpn. 48: 667-670， 2002) 






























あった. (血清): ACTH 30pg/dl (7-56)， II-OHCS 
24.6μg/dl (8-30)，∞rtisol 22.2μg/dl (4.0-23.3)， 
aldosterone 1.5 ng/dl (2 -13)， testosterone 6.7 ng/ 
ml (2.70-10)， adrenaline 0.03 ng/ml (話0.17)， 
noradrenaline 0.21 ng/ml (0.15-0.57)， dopamine 
<0.02 ng/ml (孟0.03). (尿): 17-KS 8.8 mg/day 
(4.6-16)， 17-KGS 12.3mg/day (6.00-18)， 17-
OHCS 5.1 mg/day (2.9-11)， free cholesterol 210 
μg/day (11.2-80.3)， androsterone 0.14mg/day 
(1.1-4.8)， OH-androsterone 0.3mg/day (0.3-
2.1)， OH司etiocholanorone0.2 mg/day (孟0.6)，
668 泌尿紀要 48巻 1号 2002年
etiocholanorone 2.4mg/day (0.4-3.3)， DHEA 
0.5 mg/day (壬3.0)，aldosterone 4.1μg/day (0.6-
9.0)， Noradrenaline 144.0μg/day (29-120)， 
dopamine 1，岨Oμg/day(100-1，0∞)， metanephline 
0.08 mg/day (0.05-0.20)， normetanephline 0.32 













Fig. 1. Computed tomography revealed a 
large left adrenocortical carcinoma 
heterogeneously enhanced with ringed 
calcification. 
Fig. 2. T2-weighted MRI demonstrated low 




















Fig. 3. Gross appearance of removed tissue. 
The tumor was adherent to the left 
kidney. 
Fig. 4. Histopathological findings showed 
eosinophilic and pleomorphic tumor 
cells with irregular and lobulated nu-
clei. Multiple foci of necrosis， calcifi-
cation and ossification with intense 
neutrophilic infiltration were present 





























Computed tomography before and after 
chemotherapy. A: 3 months a仇erop-
eration at local recurrence. B: 4 
months after operation. The mass in-
creased in size. Chemotherapy was im-
mediately started. C: 5 months after 
operation (after 1 chemotherapy cyde). 
D: 6 months after operation (after 2 
chemotherapy cydes). No favorable re-
sponse to chemotherapy was observed. 
mitotane療法2) (1コース=28days; 0， p'-DDD 
(mitotane) は 4g/dayで継続・ ADM20mg/m2 
(day 1， 8) CDDP 40 mg/m2 (day 1， 9) VP-16 
100 mg/m2 (day 5-7))を2コース施行した.
















のに対し， stage 111; stage IVでは明らかに低くな
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